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Abstract
Background: Estradiol (E2) and progesterone (P) are well known regulators of progesterone receptor
(PR) expression in the rat uterus. However, it is not known which receptor subtypes are involved. Little
knowledge exist about possible differences in PR regulation through ERalpha or ERbeta, and whether the
PR subtypes are differently regulated depending on ER type bound. Thus, in the present study PR
immunostaining has been examined in uteri of ovariectomized (ovx) rats after different treatments of
estrogen and P, in comparison with that in immature, cycling, and pregnant animals.
Methods: The uteri were collected from 1) ovx rats treated with E2 and/or P; 2) immature rats, intact
cycling rats and animals pregnant day 8 and 18; 3) ovx rats treated with E2 or an estrogen receptor
(ER)alpha agonist or an ERbeta agonist. Two antibodies were used, one detecting PRA+B and another one
specific for PRB. Real-time PCR was used to determine mRNA levels for PRAB and PRB in experiment 3.
Results: In stroma and myometrium faint staining was detected in ovx controls (OvxC), whereas E2
treatment resulted in strong staining. In contrast to this, in luminal epithelium (LE) the staining was strong
in the OvxC group, whereas E2 treatment during the last 24 hrs before sacrifice caused a decrease. Similar
to OvxC the LE of the immature animals was strongly stained. In the pregnant rats LE was negative, well
in agreement with the results seen after E2 treatment. In the pregnant animals the stroma and decidua was
strongly stained for PRAB, but only faint for PRB, indicating that PRA is the most expressed isoform in this
state. The increase in stromal and myometrial immunostaining after E2 treatment was also found after
treatment with the ERalpha agonist PPT. The ERbeta agonist DPN caused a decrease of the PR mRNA
levels, which was also found for PRAB and PRB immunostaining in the GE.
Conclusion: Stromal and myometrial PRAB levels are increased via ERalpha, as shown by treatment with
E2 and the ERalpha agonist PPT, while the levels in LE are decreased. The uterine stroma of pregnant rats
strongly expressed PRAB, but very little PRB, which is different to E2 treated ovx animals where both
PRAB and PRB are strongly expressed. The ERbeta agonist DPN decreased the mRNA levels of PRAB and
PRB, as well as the PRAB protein level in GE. These results suggest that ERbeta signals mainly down-
regulate PR levels in the epithelial cells. ERalpha, on the other hand, up-regulates PR levels in the stroma
and myometrium while it decreased them in LE. Thus, the effects from E2 and PPT on the mRNA levels,
as determined by PCR, could be annihilated since they are increased and decreased depending on cell type.
The distribution and amount of PR isoforms strongly depend on the hormonal milieu and cell type within
the rat uterus.
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Background
Progesterone (P) together with estrogen provides the basis
for the cyclic changes in the uterine tissues during the
estrous cycle. Stromal-epithelial interactions have been
shown to be critical in the regulation of epithelial cells by
estradiol (E2) and P [1]. The actions of E2 and P are pri-
marily mediated via binding to specific intracellular
receptors in the target cells. The estrogen receptor (ER)
and progesterone receptor (PR) are members of a super-
family of nuclear transcription factors with highly homol-
ogous DNA binding and ligand binding domains [2-6].
PR exists in two major isoforms, A and B [7]. The two iso-
forms arise due to use of different promoters, thus creat-
ing two separate mRNAs. It has been shown that PR is
localized in the nuclei of epithelial, stromal and smooth
muscle cells in the uterus of normal cycling rats [8,9]. In
addition, estrogens increase the PR immunoreaction in
stromal, but not epithelial, cells in ovariectomized (ovx)
rats. Thus, these results made Ohta et al. conclude that
uterine PR expression is regulated by ovarian steroids dur-
ing the estrous cycle and early pregnancy [8].
After the discovery of ER subtype (β) [2], the hormonal
signals are now assumed to be transduced by both forms
of ER, α and β [2-5]. Both ERs bind E2 with high affinity
and specificity [10]. Although ERβ shares many functional
characteristics with ERα, the molecular mechanisms regu-
lating the transcriptional activity and the tissue location of
ERβ are distinct from those of ERα [2,10].
In ovx rats, E2 induces DNA synthesis and mitosis in the
uterus, whereas P inhibits DNA synthesis in the epithe-
lium, but stimulates mitosis in the stromal cells [11,12].
ERα turns on target gene expression and functions as a
regulator of ligand-activated transcription in estrogen
responsive tissues [13], whereas P attenuates cell sensitiv-
ity to E2 by decreasing ERα levels [14]. It has been shown
that nuclear ERα levels decrease in the rat uterus as serum
P levels increase [15], and that P decreases sensitivity of
cells to estrogens by inhibiting ER-mediated transactiva-
tion via direct interactions of ligand bound PR and ERα
[16].
The aim of the present study was to determine the distri-
bution of PR, also regarding subtype, in the rat uterus dur-
ing different hormonal conditions. We also aimed at
detecting possible differences between stimulation by
ERα and ERβ. We have studied PRAB and PRB immunos-
taining in the uteri of ovx rats treated with an ERα agonist,
an ERβ agonist, E2 and/or P and for comparison the
results from immunostaining of immature animals, intact
cycling animals and during pregnancy is also shown.
Methods
Animals
All rats were purchased from Scanbur-BK AB, Sollentuna,
Sweden. The animals were housed in a controlled envi-
ronment at 20°C on an illumination schedule of 12 h of
light and 12 h of darkness each day. Standard pellet food
and water were provided ad libitum. The animal studies
were approved by the Committee on Animal Care in Swe-
den.
Experiment 1. Forty-one adult female Sprague-Dawley rats,
55–60 days old, were ovariectomized under light ether
anaesthesia and housed for 14 days before initiation of
hormone treatment. They were treated with 1 μg 17β-
estradiol (E2)/100 g bw and/or 0.4 mg progesterone (P)/
100 g bw as shown in Table 1. The designation of the
treatment groups as described in Table 1 will be used in
the text.
Experiment 2. Four groups of 6 rats each, see Table 2 for a
more precise description of the rats. The pregnant rats (n
= 12) arrived at the animal department on day 4 of preg-
nancy together with their non-pregnant littermates (n =
6). The pregnant rats were sacrificed on day 8 (n = 6) and
18 (n = 6) of pregnancy. Group I: Immature 21-days old.
Group II: Intact cycling rats 8 weeks old, vaginal smear
Table 1: Experiment 1
Experimental Group Day 1 (8 am) treatment Day 2 (8 am) treatment Day 3 (8 am) Uterine weight (g)
OvxC (n = 5) vehicle vehicle sacrifice 0.092a ± 0.008
24E (n = 6) E2 sacrifice 0.162bcd* ± 0.019
24P (n = 6) P sacrifice 0.122abc ± 0.013
48E (n = 6) E2 E2 sacrifice 0.215b* ± 0.039
48P (n = 6) P P sacrifice 0.098ad ± 0.008
24E+24P (n = 6) E2 P sacrifice 0.145abc ± 0.012
24P+24E (n = 6) P E2 sacrifice 0.170c* ± 0.018
The rats were injected s.c. in the neck with either vehicle (propyleneglycol), 10 μg E2/kg rat, or 4 mg P4/kg rat, or combinations of these. 
Experimental animals were sacrificed after 24 or 48 hours of hormone treatment, respectively. The uterine wet weight is presented in grams (mean 
± SD). Numbers (right column) without any common superscript letters indicate a significant (p < 0.05) difference in uterine weight. The asterisk 
(*) indicates a significant (p < 0.05) difference in uterine weight as compared to OvxC.Reproductive Biology and Endocrinology 2006, 4:47 http://www.rbej.com/content/4/1/47
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was take n at sacrifice to determine stage of estrous cycle.
Group III: 8-days pregnant rats. From group III one rat was
deleted due to lack of embryos, i.e. it was not pregnant.
Group IV: 18-days pregnant rats. From group IV one rat
was deleted since it carried only one embryo, which was
very different to the others who carried between 9–13
embryos each. Group III and IV therefore have n = 5.
Experiment 3. Thirty-two female adult Sprague-Dawley
rats, 55–60 days old and weighing approximately 250 g
were used. The rats were ovariectomized during anesthe-
sia with Xylazin (Bayer AG, Leverkusen, Germany; 0.75
mg/100 g rat) and Ketaminol (Intervet AB, Boxmeer,
Netherlands; 7 mg/100 g rat). They were housed for 14
days before initiation of hormone treatment. The ovx ani-
mals were treated with one single s.c. injection with 2 μg
E2/100 g bw, 0.5 mg PPT (4,4',4"-(4-Propyl- [1H]-pyra-
zole-1,3,5-triyl)trisphenol)/100 g bw or 1.25 mg DPN
(2,3-bis(4-hydroxy-phenyl)-propionitrile)/100 g bw 18
hrs prior to sacrifice. The uterine weight of the PPT treated
animals was higher than for the other three groups (p <
0.05), and the uterine weight of the E2 treated rats was
higher than for the OvxC and DPN groups (p < 0.05; data
not shown). Thus, the estrogenic effect of PPT binding to
ERα was even stronger than that of E2 in this experiment,
while DPN had no effect on uterine weight.
The non-steroidal compounds PPT and DPN were
recently developed and characterized as selective agonists
for ERα and ERβ, respectively. PPT is approximately 1000-
fold more potent as an agonist on ERα than on ERβ and
has a 400-fold preference towards ERα in its binding affin-
ity [17,18]. DPN has a 70-fold higher relative binding
affinity and 170-fold higher relative potency in transcrip-
tion assays with ERβ than with ERα [19]. 17β-estradiol
has equal affinity for ERα and ERβ [10]
Hormones
E2 and P were purchased from Sigma Co. (St. Louis, Mis-
souri). The hormones were dissolved in 99.5% ethanol at
a high concentration and then diluted in propyleneglycol
to the proper concentration. The final concentration of
ethanol was less than 5% in the injections. The substances
were injected in 200 μl. The OvxC group received vehicle
(propyleneglycol).
For experiment 3 E2 was dissolved in 99.5% ethanol at a
high concentration and then diluted with 50:50
DMSO:PBS to the proper concentration. The final concen-
tration of ethanol was less than 2% in the injections. PPT
and DPN were bought from Tocris Cookson, via Bio
Nuclear, Bromma, Sweden, and were dissolved in DMSO
and then diluted with PBS until the proper concentration
and a dilution of 50:50 DMSO:PBS. The control group
was treated with the vehicle (DMSO:PBS 50:50).
Tissue collection
During anesthesia, the rat uterus was removed, stripped of
fat and connective tissue, weighed and immersion-fixed in
4% formaldehyde for 8 hours and stored in 70% ethanol
at 4°C and thereafter embedded in paraffin. In experi-
ment 3 a small piece of uterus was also directly frozen in
RNAlater (Ambion) and stored at -20°C until RNA prep-
aration.
Immunohistochemistry
Paraffin sections (5 μm) were used and a standard immu-
nohistochemical technique (avidin-biotin-peroxidase)
was utilized as described before [20], to visualize PRAB
and PRB immunostaining intensity and distribution.
There were 2–4 sections from every uteri/slide and there
was always a positive and negative control included for
every assay. When possible all samples in an experiment
are run in the same assay to minimize variability due to
technical handling. Only experiment 1 had to be divided
into two separate assays, and then half of the slides in each
group were run in each run to avoid any systematic error.
Since PRA is basically impossible to detect by immunohis-
tochemistry, we have used one antibody which detect
only PRB and one that binds both PRA and PRB. The dif-
ferences in results obtained by the two antibodies should
though be interpreted with caution, since it is difficult to
draw conclusions on the expression of PRA when the
affinities of each antibody are not the same. There is an
antibody detecting human PRA available (Novacastra,
clone 16, binds PRA in immunohistochemistry and
PRA+PRB in Western blot)[21], but it does not work in rat
tissue (data not shown). Monoclonal mouse anti-human
antibodies were used for detection of PRAB (MA1-410,
Affinity Bioreagents Inc.) and PRB (MA1-411, Affinity
Bioreagents Inc.). The primary antibody was replaced by
normal mouse IgG to obtain negative controls. ThePRAB
antibody was diluted 1:100 in PB S and incubated on sec-
tions at 4°C overnight. The PRB antibody was diluted
1:100 in PBS, and incubated on sections at RT for 60 min.
Table 2: Experiment 2
Experimental group Uterine weight (g) Number of pups
Immature (n = 6) 0.03 ± 0.00a -
NC§ (n = 6) 0.29 ± 0.059ab -
Pregnant day 8 (n = 5) 0.57 ± 0.062#bc 11–15
Pregnant day 18 (n = 5) 25.8 ± 4.06#c 9–13
§ NC = normal cycling controls, three in metestrus, two in proestrus 
and one in diestrus
# including placenta
Uterine weights and number of pups in the different groups. The 
uterine wet weight is presented in grams (mean ± SD). Numbers 
without any common superscript letters are significantly different in 
uterine weights.Reproductive Biology and Endocrinology 2006, 4:47 http://www.rbej.com/content/4/1/47
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Following primary antibody binding, the sections were
incubated with the second antibody, a biotinylated horse
anti-mouse IgG (Vectastain, Vector, Laboratories, CA)
diluted in normal horse serum, for 30 min at RT. Thereaf-
ter the tissue sections with PRAB were incubated for 30
minutes and with PRB for 60 minutes at RT with a horse-
radish peroxidase-avidin biotin complex (Vectastain Elite,
Vector, Laboratories, CA). The site of the bound enzyme
was visualized by the application of 3,3'-diaminobenzi-
dine (DAB kit, Vector, CA), a chromogen, which produces
a brown, insoluble precipitate when incubated with
enzyme. The sections were counterstained with haema-
toxylin and dehydrated before they were mounted with
Pertex (Histolab, Gothenburg).
Manual scoring
One observer blinded to the identity of the slides, per-
formed the assessment twice for the IHC scoring of exper-
iment 1 and 2. The staining was evaluated semi-
quantitatively using a grading system. The staining inten-
sity was graded on a scale of (0) = no staining, (1) faint
staining, (2) moderate staining and (3) strong staining.
Image analysis
A Leica microscope connected to a computer using Color-
vision software (Leica Imaging System Ltd. Cambridge,
England) was used to assess immunostaining quantita-
tively by a computer image analysis system. Quantifica-
tion of immunostaining was performed on the digitized
images of systematic randomly selected fields of endome-
trial stroma, from which non-stromal elements (e.g. lumi-
nal epithelium, glandular epithelium and myometrium)
were interactively removed and analyzed separately. All
luminal epithelia, all glands, as well as 10 fields of stromal
cells and 10 fields of myometrium were measured sepa-
rately in each tissue section. By using colour discrimina-
tion software, the total area of positively stained cells
(brown reaction product) was measured, and expressed as
a ratio of the total area of cell nuclei (brown reaction
product + blue haematoxylin).
RNA isolation
Uterine tissue was placed in a RNA stabilization solution
(RNAlater®, Ambion, Austin, TX) immediately after collec-
tion and stored at -20°C. Total RNA from 20 mg uterine
tissue from each animal was purified with the RNeasy® kit
(Qiagen GmbH, Hilden, Germany) according to a proce-
dure recommended by the manufacturer for RNA isola-
tion from fibrous tissues.
Reverse transcription
Two μg of total RNA from each sample was reverse tran-
scribed at 37°C for 60 min in a final volume of 20 μl with
a reaction mixture (Qiagen GmbH, Hilden, Germany)
containing 1 × RT buffer, dNTP mix (0.5 mM each dNTP),
300 ng random primers (Invitrogen, Paisley, UK), 10
units RNase inhibitor (Superase-In, Ambion, Austin, TX),
and 4U of Omniscript™ reverse transcriptase (Qiagen).
Real time PCR for PRAB, PRB and RPLP0
Real time PCR was performed in a DNA Engine Opticon™
2 System (MJ Research, Waltham, MA). For PCR, the
cDNAs corresponding to 100 ng RNA were added to 10 μl
of Quantitect™ SYBR® Green PCR mix (Qiagen) containing
HotStarTaq DNA polymerase, PCR buffer, dNTP mixture
and 0.3 μM of each oligonucleotide primer in a final vol-
ume of 20 μl. The reactions were performed in opaque
white 0.2 ml low-profile strip tubes sealed with optical flat
caps (TLS-0851, TCS-0803, MJ Research, Waltham, MA).
After initial incubation for 15 min at 95°C, the samples
were subjected to 40 cycles of 10s at 94°C, 15s at 60°C
(RPLP0 (ribosomal protein, large, P0) 57°C) and 20s at
72°C with a final extension step at 72°C for 5 min. All
reactions were performed twice. The amount of PCR prod-
ucts for PRAB, PRB and RPLP0 increased linearly up to 24,
25 and 21 cycles, respectively. The purity of PCR products
was confirmed by a melting curve analysis in all experi-
ments (data not shown). The oligonucleotide primers for
PRAB, PRB and RPLP0 are listed in Table 4. All primers
were designed to span an intron/exon boundary or to
flank an intron, thus, amplification of contaminating
DNA was eliminated. Each PCR assay included a negative
control containing a RNA sample without reverse tran-
scription.
Quantification of mRNA
To standardize the quantification method, RPLP0 was
selected out of several tested housekeeping genes as an
invariable internal control. The PCR amplification rate
and the cycle threshold (Ct) values were related to a stand-
ard curve using Opticon Monitor 3.0 software (MJ
Research, Waltham, MA). The values of relative expression
of genes of interest were normalized against the RPLP0
product.
Statistics
Statistical calculations on the results from the hormone
treated animals were performed by ANOVA on ranks
(Kruskal-Wallis test) followed by Dunn's test for evalua-
tion of significance. The results are presented as box and
whisker plots. Values with an asterisk are significantly dif-
ferent (p < 0.05) to OvxC.
Results
Estradiol and progesterone treatment (experiment 1)
PRAB. Immunostaining in the stroma was faint in the
OvxC rats (Fig 1A), but was significantly increased in all
groups receiving E2 at any time (Fig. 2, top panel, Fig
1B,D,F,G). The values showed a tendency to increase in
groups 24P and 48P but did not reach significant levelsReproductive Biology and Endocrinology 2006, 4:47 http://www.rbej.com/content/4/1/47
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(Fig. 2, top panel, Fig 1C,E). In LE staining was strong in
the OvxC (Fig 1A), but decreased in all groups that were
treated with E2 the last 24 hrs before sacrifice (Fig 2, mid-
dle panel; Fig 1B,D,G). The staining of LE in the rats of
group 24P, 48P and 24E+24P did not differ compared
with OvxC (Fig 2, middle panel; Fig 1C,E,F). There was no
staining in the myometrium of the OvxC group, but there
was strong staining in all groups receiving E2 the last 24
hrs before sacrifice (Fig 2, bottom panel). The groups
treated with P the last 24 hrs before sacrifice did not differ
in immunostaining of the myometrium compared with
the OvxC group (Fig 2, bottom panel). None of the treat-
ment groups were different from OvxC in PR expression
of the GE (data not shown).
PRB. There was faint staining in the uterine stroma of the
OvxC group (Fig 1I), but E2 treatment the last 24 hrs
before sacrifice resulted in strong staining (Fig. 3, top
panel; Fig 1J,L,O). P treatment the last 24 hrs before sacri-
fice showed an intermediary type of staining, but it was
not different from either OvxC or the E2 treated animals
(Fig 3, top panel; Fig. 1K,M,N). The PRB immunostaining
in the LE of the OvxC group was very strong (Fig 1I), but
was decreased in the groups that received E2 the last 24
hrs before sacrifice (Fig 3, middle panel; Fig 1J,L,O). The
24P and 48P groups showed a similar strong staining as
the controls (Fig 1K,M), whereas the 24E+24P group
showed an intermediary type of staining (Fig 1N), not sig-
nificantly different from either OvxC or E2 treated groups
(Fig 3, middle panel). There was very faint staining in the
myometrium of the OvxC group (Fig 3, bottom panel, Fig
1I). E2 treatment during the last 24 hrs prior to sacrifice
resulted in very strong immunostaining of the myo-
metrium (Fig 3, bottom panel; Fig 1J,L,O). In the GE none
of the treatment groups were different to the OvxC group
(data not shown). Normal mouse IgG replaced the pri-
Scoring results PRAB experiment 1 Figure 2
Scoring results PRAB experiment 1. Results from man-
ual scoring of PRAB immunohistochemistry results in stroma 
(upper panel), luminal epithelium (LE, middle panel) and myo-
metrium (bottom panel). The "box-and-whisker plot" repre-
sents the median value with 50% of all data falling within the 
box. The whiskers extend to the 5th and 95th percentiles. 
An asterisk indicates a significant (p < 0.05) difference com-
pared to the OvxC group.
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  Immunohistochemistry experiment 1 Figure 1
Immunohistochemistry experiment 1. Representative 
images of immunohistochemical results from each hormone 
treatment group in experiment 1, PRAB A-H, PRB I-O. 
Treatment groups are as follows: OvxC: A and I, 24E: B and 
J. 24P: C and K, 48E: D and L, 48P: E and M, 24E+24P: F and 
N, 24P+24E: G and O. Magnification bar 30 μm in images A-
H and 50 μm in images I-O.Reproductive Biology and Endocrinology 2006, 4:47 http://www.rbej.com/content/4/1/47
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mary antibodies to obtain negative controls for the immu-
nohistochemistry assays, the result was completely
negative (Fig 1H).
Pregnancy (experiment 2)
PRAB. There was strong immunostaining in LE and GE of
the immature animals, whereas it was faint in stroma and
myometrium (Fig. 4A, Table 3). In the cycling intact con-
trols (8 weeks old) there was faint staining in the LE and
GE of the rats in proestrus (Fig. 4B) and moderate staining
in the LE of a rat in diestrus (Fig. 4C). In stroma there was
faint staining in all rats but the one in late proestrus,
which was strong (Table 3). The staining of the myo-
metrium was moderate in most cycling animals (Table 3).
The stroma and decidua was strongly stained in the ani-
mals pregnant at day 8 (Table 3, Fig 4D,E), while LE and
GE were negative (Fig. 4D, Table 3). The placenta was neg-
ative, but the decidua still strongly stained, in the rats
pregnant on day 18 (Table 3, Fig. 4G,H).
PRB. There was strong PRB immuno-staining in the LE but
moderate in the GE of the immature rats (Table 3), and
there was faint staining in the stroma and myometrium
(Table 3). In the cycling animals there was faint or no
staining in LE, GE and stroma of all animals but one in
diestrus. In the myometrium of the rat in late proestrus
the staining was strong while the others were faint, or
moderate (Table 3). In early pregnancy the LE (Fig 4F) and
GE were negative, while the decidua was faintly stained
(Table 3). In the late pregnant group the placenta was neg-
ative and the deciduas still faintly stained (Table 3).
Estrogen receptor agonists (experiment 3)
PRAB. Stromal immunostaining increased after E2 and
PPT treatment, while no effect was found in the DPN
group (Fig. 5A,C,E,G; Fig 6 top panel). In LE E2 and PPT
treatment resulted in decreased PRAB immunostaining,
from nearly 100% to around 60%, while DPN had no
effect (Fig. 5A,C,E,G; Fig 6 second panel). In the myo-
metrium there was faint staining in the OvxC group, E2
and PPT treatments increased the PRAB staining while
DPN had no effect (inserts in Fig. 5A,C,E,G; Fig. 6 third
panel). In GE both PPT and DPN decreased immunos-
taining as compared to OvxC (Fig. 6, bottom panel).
PRB. Stromal immunostaining increased after E2 and PPT
treatment, while no effect was found in the DPN group
(Fig 5B,D,F,H; Fig 7 top panel). In LE E2 and PPT treat-
ments resulted in a major decrease of PRB immunostain-
ing, from over 90% to below 20%, while DPN had no
effect (Fig 5B,D,F,H; Fig 7 second panel). In the myo-
metrium E2 and PPT treatments increased the PRB immu-
nostaining compared with the OvxC group and after DPN
treatment (inserts in Fig 5B,D,F,H; Fig. 7 third panel). PPT
decreased immunostaining in GE, as compared to OvxC
(Fig. 7, bottom panel).
Normal mouse IgG replaced the primary antibodies to
obtain negative controls for the immunohistochemistry
assays, the result was completely negative (data from this
experiment not shown; the results were similar to Fig 1H).
PR mRNA expression in (experiment 3)
Expression of PRAB mRNA decreased in the DPN treated
animals (Fig 8; upper panel). This decrease was also found
in PRB mRNA levels (Fig 8; bottom panel). We did not
find any effect of the other treatments on PR mRNA
expression in this short time study (Fig 8).
Discussion
The uteri of PR knock-out mice fail to support implanta-
tion after embryo transfer and are unresponsive to decid-
ual stimulation [22], emphasising the essential function
of progesterone stimulation for pregnancy to occur. The
selective PRB knock-out mice have normal implantation
and decidualization (reviewed in [23]. The selective
expression of PRB in the uterus (PRA knock-outs) results
in some PRB dependent proliferative activity, indicating
that PRA is required to adverse some proliferative effects
of the PRB protein [24]. This predicts that the relative lev-
els of the uterine PR isoforms can be expected to play an
important role in the responsiveness to progestins [25].
The level of PRAB in the uterine stroma is very low after
ovx, and increases after E2 and P treatment, but not signif-
icantly if the treatment is P only. Up to 50% of the PRAB
positive cells in the OvxC group are PRB positive, thus
indicating that there are cells containing both PRA and
PRB in the OvxC group. Estradiol treatment the last 24 hrs
before sacrifice increased the PRB level, while P treatment
on its own or the last 24 hrs did not cause a significant
increase in PRB positive cells. In LE the amount of PRAB
positive cells are high and they are all positive also for
PRB. Estradiol treatment the last 24 hrs before sacrifice
decreased both PRAB and PRB levels significantly.
Changes in PRB levels did not differ from PRAB, thus PRB
seems to be the dominating PR subtype in LE.
In the myometrium PR levels were low in the OvxC group,
E2 the last 24 hrs prior to sacrifice increased PR levels,
while P treatment had no effect, or when given after 24 hrs
of E2 treatment, reduced the effect from E2 stimulation.
Thus, PRAB and PRB immunohistochemistry showed
similar results. From the experiment with E2 and/or P
treatment only stroma seems to express PRA in cells not
expressing PRB, since in this compartment differences
between PRAB and PRB immunostaining are apparent. In
mice, it has been shown before that PRs are expressed in
epithelial, stromal and myometrial cells of the uterus andReproductive Biology and Endocrinology 2006, 4:47 http://www.rbej.com/content/4/1/47
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their location and temporal variation within the tissue are
regulated by both estrogens and progesterone [9,25,26].
In pregnant rats the decidua was strongly stained for
PRAB, while PRB was less strong, i.e. PRA seems to be
highly expressed in the decidua. This is in agreement with
the results from PRAB knock-out mice, where no implan-
tation and no decidual stimulation were obtained [22],
while PRB knock-outs (i.e. PRA intact) have normal
implantation and decidualization [23]. Thus, PRA is the
isoform most important for an implantation to occur. An
alternative explanation to our results would be that the
third isoforms of PR described, and named C [27] would
be the dominant form in the decidua [28]. It has been
shown that PRC is present in the cytosol, which is differ-
ent to PRA and PRB which are nuclear [29]. The immu-
nostaining of PRAB in the uteri and decidua is strictly
nuclear, see fig 4. In the uterine stroma of the early preg-
nant rats PRAB immunostaining was strong, while PRB
was very faintly expressed. Therefore, PRA seems also to be
strongly induced in the uterine stroma during early preg-
nancy. The placenta was negative for both PRAB and PRB.
The LE of the early pregnant rats was also negative, in
agreement with the findings in the animals receiving
estradiol treatment.
In immature rats both the luminal and glandular epithelia
were strongly stained for PRAB and PRB, while stroma and
myometrium was faintly positive. In the mature cycling
animals the LE and GE are less positive for PRs while
stroma and myometrium are much stronger stained,
although varying during the cycle. Dramatic changes in PR
expression have been shown during the estrous cycle and
in early pregnancy [8]. The PR mRNA levels do not vary in
the rat uterus during the estrous cycle, suggesting that the
expression of PR is primarily regulated post-translation-
ally and/or translationally [30].
The doses of PPT and DPN were decided by comparing
data from previous articles on mice and rats [31-34]. They
showed that PPT, similarly to E2, increases uterine weight,
while no effect was found after DPN treatment. Another
group showed that DPN in this concentration has anxio-
lytic properties in the rat [33]. Thus, the doses that we
used in this short time study have previously been shown
to be effective. DPN decreased the uterine PR mRNA level
as compared to controls [31], which is in agreement with
Immunohistochemistry experiment 2 Figure 4
Immunohistochemistry experiment 2. Representative 
images of immunohistochemical results from the immature 
(A), cycling (B,C) and pregnant rats (D-H). Image F shows 
PRB immunostaining while all the others show PRAB. The 
arrow in image H indicates the negative cells in the placenta. 
Magnification bar 30 μm in all images.
Scoring results PRB experiment 1 Figure 3
Scoring results PRB experiment 1. Results from manual 
scoring of PRB immunohistochemistry results in stroma 
(upper panel), luminal epithelium (LE, middle panel) and myo-
metrium (bottom panel). The "box-and-whisker plot" repre-
sents the median value with 50% of all data falling within the 
box. The whiskers extend to the 5th and 95th percentiles. 
An asterisk indicates a significant (p < 0.05) difference com-
pared to the OvxC group.
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our present finding in this short time study. In addition,
we found that DPN also decreased the PRAB immunos-
taining of GE, which indicate that the decrease in PR
mRNA levels could be most pronounced, or selective, in
the GE. No effect on the mRNA levels was found after E2
or PPT treatment. This could be caused by the effects from
different cell types, since epithelium showed decreased
immunostaining while stroma and myometrium had
increased levels after treatment. Thus, the regulation of PR
protein levels via ERα found, could be caused by transla-
tional regulation, or taking place post-translationally via
regulation of other regulatory proteins. A third plausible
explanation is that the ERα mediated effects on PR mRNA
levels could be obscured due to the mixture of cell types
in the uterine homogenate used for PCR. Further in situ
hybridization studies would be informative on PR mRNA
regulation by E2 and PPT in the different cell types.
It has been shown that immunohistochemical staining of
uterine PR decrease in epithelial cells after E2 treatment in
immature mice, in agreement with our results on ovx rats,
and those from ERβ knock-out animals [35]. Thus, E2
dependent down regulation of epithelial cells in the
uterus would be at least partly ERβ dependent. On the
other hand, results from E2 treatment of ERα knock-out
mice showed that the PR protein is up-regulated in uterine
epithelium, and the level is not possible to decrease by E2
treatment in the ERα knock-out mice, indicating that the
low level of ERβ in uterine epithelium is not capable of
substituting for the absence of ERα [26]. The elegant
experiments performed by Kurita et al. on tissue cultures
of stroma and epithelium from different combinations of
wt and ERaKO suggest that E2 induced down-regulation
of epithelial PR in the uterus is mediated through para-
crine mechanisms mediated via ERα [26]. We found
though, that DPN treatment caused down regulation of
the PR protein level in GE, and indeed it also decreased
the PRAB and PRB mRNA levels. Therefore, epithelial PR
expression (especially glandular) in the uterus is likely to
be, at least partly, regulated via ERβ.
Conclusion
The results of the present study indicate that ERα activity
up-regulate PR concentrations in the stroma and myo-
metrium, while it down-regulates the levels in epithelial
cells. ERβ signalling decrease the PR mRNA levels, possi-
Table 3: Immunostaining results from the rats in experiment 2
Experimental Group (rat number) PRAB PRB
Immature (n = 6) LE GE Stroma Myomet LE GE Stroma Myomet
1 +++ 0 + + +++ 0 + +
2 na
3 na
4 +++ +++ + (+) +++ ++ + +
5 na
6 +++ +++ + (+) +++ ++ + +
NC (n = 6)
1 (metestrus) - + (+) + lost lost lost lost
2 (proestrus) + + + ++ + (+) (+) +
3 (metestrus) - - + ++ + + + +
4 (late proest) - + +++ +++ - - + +++
5 (diestrus) +++ + ++ ++ +++ ++ ++ ++
6 (metestrus) (+) + (+) ++ + + (+) +
Pregnant day 8(n = 5) Decidua Decidua
1 - - +++ +++ - - (+) +
2 - - +++ +++ - - (+) +
3 - - +++ +++ - - (+) +
4 - - +++ +++ - - (+) +
5- - + + + + + - - ( + ) +
Pregnant day 18 (n = 5) Placenta Decidua Placenta Decidua
1- + + + - +
2- + + + - +
3- + + + - +
4- + + + - +
5- + + + - +
na = not available 0 = no gland – = no stainingReproductive Biology and Endocrinology 2006, 4:47 http://www.rbej.com/content/4/1/47
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bly selectively in the GE since in this structure the PR pro-
tein is also down regulated after DPN treatment. Thus, the
distribution and amount of PR isoforms are depending on
the hormonal milieu, the cell type within the rat uterus, as
well as the subtype of ER that is activated.
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Image analysis PRAB experiment 3 Figure 6
Image analysis PRAB experiment 3. Results from image 
analysis of PRAB immunohistochemistry results in stroma 
(upper panel), luminal epithelium (LE, second panel), myo-
metrium (third panel) and glandular epithelium (GE, bottom 
panel). The "box-and-whisker plot" represents the median 
value with 50% of all data falling within the box. The whiskers 
extend to the 5th and 95th percentiles. An asterisk indicates 
a significant (p < 0.05) difference compared to the OvxC 
group.
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Immunohistochemistry experiment 3 Figure 5
Immunohistochemistry experiment 3. Representative 
images of immunohistochemical results from the agonist 
treated rats, PRAB in left columnand PRB in right column. 
Representative images are shown from a rat in each treat-
ment group as follows: OvxC (A,B), E2 (C,D), PPT (E,F) 
and DPN (G,H). The insert shows the myometrium from 
the same uterus. Magnification bar 30 μm.Reproductive Biology and Endocrinology 2006, 4:47 http://www.rbej.com/content/4/1/47
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Real-time PCR experiment 3 Figure 8
Real-time PCR experiment 3. Representative real-time 
PCR experiments for expression of PRAB (upper panel) and 
PRB (bottom panel) mRNAs in uterus from rats subjected to 
treatment with E2, PPT and DPN. The values of relative 
expression of target genes were normalized against RPLP0 
and displayed in arbitrary units. The "box-and-whisker plot" 
represents the median value with 50% of all data falling within 
the box. The whiskers extend to the 5th and 95th percen-
tiles. An asterisk indicates a significant (p < 0.05) difference 
compared to the OvxC group.
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Image analysis PRB experiment 3 Figure 7
Image analysis PRB experiment 3. Results from image 
analysis of PRB immunohistochemistry results in stroma 
(upper panel), luminal epithelium (LE, second panel), myo-
metrium (third panel) and glandular epithelium (GE, bottom 
panel). The "box-and-whisker plot" represents the median 
value with 50% of all data falling within the box. The whiskers 
extend to the 5th and 95th percentiles. An asterisk indicates 
a significant (p < 0.05) difference compared to the OvxC 
group.
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Table 4: Oligonucleotide primers used for real-time PCR in experiment 3.
Gene Accession No. Primers Position
PRAB NM_022847 Forward CAGGCCGCGGTGCTCAA bp 1546–1572
Reverse GTGGGCTCTGGCTGGCTTCT bp 1636–1617
Product 91 bp
PRB U06637 Forward CAGACCAACCTGCAACCAGAA bp 1471–1491
Reverse AGTCCTCACCAAAACCCTGGG bp 1592–1572
Product 122 bp
RPLP0 NM_001002 Forward GGCGACCTGGAAGTCCAACT bp 195–214
Reverse CCATCAGCACCACAGCCTTC bp 343–324
Product 149 bpReproductive Biology and Endocrinology 2006, 4:47 http://www.rbej.com/content/4/1/47
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